시장보고서

상품코드

1552627

세계의 항정신병약 시장 - 규모, 점유율, 동향 분석 보고서 : 질환별, 약제별, 치료제 클래스별, 유통채널별, 지역별, 부문 예측(2024-2030년)

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 08월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

항정신병 약물 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 항정신병 약 시장 규모는 2030년까지 249억 7,000만 달러에 달했으며 2024년부터 2030년까지의 CAGR은 6.1%를 나타낼 것으로 예측됩니다.

기존 제품의 부작용과 바람직하지 않은 반응을 극복하기 위해, 보다 우수한 차세대 제품이 지속적으로 개발되고 있는 것이 신제품에 대한 수요를 창출하고 있습니다. 이것이 시장을 촉진할 것으로 예상됩니다.

항정신병 약물의 급성장은 정신병 및 기타 정신 장애의 유병률 증가로 인한 것입니다. 각국 정부는 정신건강 및 정신질환에 대한 의식 향상에 힘을 쏟고 있으며, 항정신병약 수요를 더욱 밀어올릴 것으로 예상됩니다. 정부기관은 대기업과 협력하여 사회에 존재하는 정신병성 장애와 관련된 낙인을 해소하기 위한 사회적 프로그램을 실시했습니다.

불면증, 갈증, 졸음, 눈 흐림 등 항정신병 약물의 부작용은 환자의 수용 수준을 낮추면 성장에 영향을 미칠 것으로 예상됩니다. 또한, 의존성, 습관 형성 및 중독의 가능성은 이러한 약물의 채용에 영향을 미칩니다.

2011년 10월에 Zyprexa는 2012년에 Seroquel와 Risperdal가 특허 보호를 잃어가고 이 약들 시장 성장을 방해했습니다. 또 제네릭 의약품 진입도 기존 브랜드의 성장을 둔화시켰습니다.

항정신병 약물 시장 보고서 하이라이트

2023년 시장수익 점유율은 정신분열증이 39.2%로 최대. 정신 분열증은 심각한 정신 질환이며 세계 많은 사람들에게 영향을 미칩니다.
아리피프라졸은 2023년 최대 시장 점유율을 차지했습니다. 이 부문의 판매는 3세대 제품의 채용으로 증가합니다. 또한 제품 승인이 예측 기간 동안 가장 큰 성장을 이룰 것으로 예상됩니다.
브렉스피프라졸은 예측 기간 동안 가장 빠른 CAGR 9.8%를 기록할 전망입니다.
2세대 치료제 클래스는 2023년 62.9%의 최대 시장 수익 점유율을 차지했습니다. 이 부문의 성장은 하파이라, HAFYERA, INVEGA, SEROQUEL, XR, ZYPREXA 등 시장에서 입수할 수 있는 수많은 2세대 의약품의 존재로 인한 것입니다.
소매 약국 부문은 시장을 독점하고 2023년에 가장 큰 점유율을 차지했습니다. 소매 약국은 환자가 쉽게 사용할 수 있으며 처방약이 필요한 환자의 첫 번째 창구가되는 경우가 많습니다.
북미가 시장을 독점했으며 2023년 수익 점유율은 37.67%였습니다. 이 지역 시장 지배로 인한 중요한 요인으로는 지역의 정신 질환의 강한 유병률, 유명한 바이오 의약품 기업 시장 존재 등이 있습니다.

항정신병약 시장 점유율, 지역별, 2023년 및 2030년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 남아프리카
- 쿠웨이트

제9장 경쟁 구도

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 프로파일
- H.Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Janssen Global Services, LLC
- Eli Lilly and Company
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Sumitomo Pharma
- Alkermes
- Bristol-Myers Squibb Company

JHS 24.09.24

Antipsychotic Drugs Market Growth & Trends:

The global antipsychotic drugs market size is expected to reach USD 24.97 billion by 2030, growing at CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The continuous development of better next-generation products to overcome adverse effects and unwanted reactions of existing products is creating demand for newer products. This factor is anticipated to propel the market.

Rapid growth of antipsychotics can be attributed to the rising prevalence of psychosis and other mental disorders. Governments are focused on creating awareness regarding mental health and psychological illnesses, which is further anticipated to drive the demand for antipsychotics. Government bodies in collaboration with major players conduct social programs to break the stigma related to psychotic disorders that exists in the society.

Adverse effects of antipsychotics, such as insomnia, dry mouth, drowsiness, and blurred vision, are expected to affect the growth by decreasing the level of acceptance in patients. In addition, the possibility of dependency, habit formation, or addiction is affecting the adoption of these drugs.

Established brands such as, Zyprexa lost patent protection in October 2011, followed by Seroquel and Risperdal in 2012, which hampers the market growth for these drugs. Also, the entry of generic versions of these products slowed the growth of the already existing brands.

Antipsychotic Drugs Market Report Highlights:

Schizophrenia accounted for the largest market revenue share of 39.2% in 2023. Schizophrenia is a serious mental illness that impacts a significant amount of individuals worldwide.
Aripiprazole accounted for the largest market revenue share in 2023. The sales of this segment increase with the adoption of third-generation products. Furthermore, it is anticipated that product approvals are expected to experience the most significant growth during the projected period.
Brexpiprazole is expected to register the fastest CAGR of 9.8% during the forecast period.
The second generation therapeutic class accounted for the largest market revenue share of 62.9% in 2023. The growth of this segment can be attributed to the presence of a number of second-generation medications available in the market, such as HAFYERA, INVEGA, SEROQUEL, XR, ZYPREXA, and others.
The retail pharmacies segment dominated the market and accounted for the largest share in 2023. Retail pharmacies are easily available to patients, and they often act as the initial point of contact for individuals in need of prescription medications.
North America dominated the market with revenue share of 37.67% in 2023. Some of the critical factors attributable to the region's market dominance include the strong prevalence of psychiatric illnesses in the region and the market presence of prominent biopharmaceutical companies.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Antipsychotic Drugs Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Antipsychotic Drugs Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Antipsychotic Drugs Market: Disease Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Antipsychotic Drugs Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
4.3. Schizophrenia
- 4.3.1. Schizophrenia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Bipolar Disorder
- 4.4.1. Bipolar Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Unipolar Disorder
- 4.5.1. Unipolar Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Dementia
- 4.6.1. Dementia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Others
- 4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Antipsychotic Drugs Market: Drug Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Antipsychotic Drugs Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
5.3. Risperidone
- 5.3.1. Risperidone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Quetiapine
- 5.4.1. Quetiapine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Olanzapine
- 5.5.1. Olanzapine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Aripiprazole
- 5.6.1. Aripiprazole Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Brexpiprazole
- 5.7.1. Brexpiprazole Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Paliperidone Palmitate
- 5.8.1. Paliperidone Palmitate Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Others
- 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Antipsychotic Drugs Market: Therapeutic Class Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Antipsychotic Drugs Market: Therapeutic Class Movement Analysis, 2023 & 2030 (USD Million)
6.3. First Generation
- 6.3.1. First Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Second Generation
- 6.4.1. Second Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Third Generation
- 6.5.1. Third Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Antipsychotic Drugs Market: Distribution Channel Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Antipsychotic Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
7.3. Hospital Pharmacies
- 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Retail Pharmacies
- 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Online Pharmacies
- 7.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Antipsychotic Drugs Market: Regional Estimates & Trend Analysis

8.1. Antipsychotic Drugs Market Share, By Region, 2023 & 2030 (USD Million)
8.2. North America
- 8.2.1. North America Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.2. U.S.
  - 8.2.2.1. U.S. Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.3. Canada
  - 8.2.3.1. Canada Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.2.4. Mexico
  - 8.2.4.1. Mexico Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. Europe
- 8.3.1. Europe Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.2. U.K.
  - 8.3.2.1. U.K. Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Germany
  - 8.3.3.1. Germany Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.4. France
  - 8.3.4.1. France Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Italy
  - 8.3.5.1. Italy Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.6. Spain
  - 8.3.6.1. Spain Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.7. Denmark
  - 8.3.7.1. Denmark Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.8. Sweden
  - 8.3.8.1. Sweden Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.3.9. Norway
  - 8.3.9.1. Norway Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Asia Pacific
- 8.4.1. Asia Pacific Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.2. China
  - 8.4.2.1. China Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Japan
  - 8.4.3.1. Japan Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.4. India
  - 8.4.4.1. India Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.5. Australia
  - 8.4.5.1. Australia Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.6. South Korea
  - 8.4.6.1. South Korea Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4.7. Thailand
  - 8.4.7.1. Thailand Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Latin America
- 8.5.1. Latin America Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.2. Brazil
  - 8.5.2.1. Brazil Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5.3. Argentina
  - 8.5.3.1. Argentina Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Middle East and Africa
- 8.6.1. Middle East and Africa Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.2. Saudi Arabia
  - 8.6.2.1. Saudi Arabia Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.3. UAE
  - 8.6.3.1. UAE Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.4. South Africa
  - 8.6.4.1. South Africa Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Kuwait
  - 8.6.5.1. Kuwait Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
- 9.4.1. H.Lundbeck A/S
  - 9.4.1.1. Participant's Overview
  - 9.4.1.2. Financial Performance
  - 9.4.1.3. Product Benchmarking
  - 9.4.1.4. Recent Developments/ Strategic Initiatives
- 9.4.2. Otsuka Pharmaceutical Co., Ltd.
  - 9.4.2.1. Participant's Overview
  - 9.4.2.2. Financial Performance
  - 9.4.2.3. Product Benchmarking
  - 9.4.2.4. Recent Developments/ Strategic Initiatives
- 9.4.3. Janssen Global Services, LLC
  - 9.4.3.1. Participant's Overview
  - 9.4.3.2. Financial Performance
  - 9.4.3.3. Product Benchmarking
  - 9.4.3.4. Recent Developments/ Strategic Initiatives
- 9.4.4. Eli Lilly and Company
  - 9.4.4.1. Participant's Overview
  - 9.4.4.2. Financial Performance
  - 9.4.4.3. Product Benchmarking
  - 9.4.4.4. Recent Developments/ Strategic Initiatives
- 9.4.5. AbbVie, Inc.
  - 9.4.5.1. Participant's Overview
  - 9.4.5.2. Financial Performance
  - 9.4.5.3. Product Benchmarking
  - 9.4.5.4. Recent Developments/ Strategic Initiatives
- 9.4.6. Teva Pharmaceutical Industries Ltd.
  - 9.4.6.1. Participant's Overview
  - 9.4.6.2. Financial Performance
  - 9.4.6.3. Product Benchmarking
  - 9.4.6.4. Recent Developments/ Strategic Initiatives
- 9.4.7. Dr. Reddy's Laboratories Ltd.
  - 9.4.7.1. Participant's Overview
  - 9.4.7.2. Financial Performance
  - 9.4.7.3. Product Benchmarking
  - 9.4.7.4. Recent Developments/ Strategic Initiatives
- 9.4.8. Sumitomo Pharma
  - 9.4.8.1. Participant's Overview
  - 9.4.8.2. Financial Performance
  - 9.4.8.3. Product Benchmarking
  - 9.4.8.4. Recent Developments/ Strategic Initiatives
- 9.4.9. Alkermes
  - 9.4.9.1. Participant's Overview
  - 9.4.9.2. Financial Performance
  - 9.4.9.3. Product Benchmarking
  - 9.4.9.4. Recent Developments/ Strategic Initiatives
- 9.4.10. Bristol-Myers Squibb Company
  - 9.4.10.1. Participant's Overview
  - 9.4.10.2. Financial Performance
  - 9.4.10.3. Product Benchmarking
  - 9.4.10.4. Recent Developments/ Strategic Initiatives

세계의 항정신병약 시장 - 규모, 점유율, 동향 분석 보고서 : 질환별, 약제별, 치료제 클래스별, 유통채널별, 지역별, 부문 예측(2024-2030년)

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

항정신병 약물 시장의 성장과 동향 :

항정신병 약물 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 항정신병약 시장의 변수, 동향, 범위

제4장 항정신병약 시장 : 질환별 추정·동향 분석

제5장 항정신병약 시장 : 약제별 추정·동향 분석

제6장 항정신병약 시장 : 치료제 클래스별 추정·동향 분석

제7장 항정신병약 시장 : 유통 채널별 추정·동향 분석

제8장 항정신병약 시장 :지역별 추정·동향 분석